Financial Performance - The company reported a revenue of 500 million RMB for the first half of 2023, representing a year-on-year increase of 20%[12] - The net profit attributable to shareholders for the same period was 100 million RMB, up 15% compared to the previous year[12] - The company's operating revenue for the first half of 2023 reached ¥1,012,077,288.18, representing a 30.27% increase compared to ¥776,881,166.02 in the same period last year[34] - The net profit attributable to shareholders of the listed company decreased by 75.58% to ¥90,627,154.09 from ¥371,119,594.26 year-on-year[34] - The net profit attributable to shareholders after deducting non-recurring gains and losses fell by 77.72% to ¥76,886,466.41 compared to ¥345,120,940.60 in the previous year[34] - The net cash flow from operating activities decreased by 54.86% to ¥246,209,748.37 from ¥545,493,427.60 in the same period last year[34] - Basic earnings per share for the first half of 2023 decreased by 75.71% to RMB 0.17 compared to the same period last year[53] - The net profit for the first half of 2023 is 89,508,170.24, a decrease from 370,384,259.65 in the same period last year, representing a decline of approximately 76.1%[142] - The total profit for the first half of 2023 is 116,935,671.75, down from 435,147,886.36 in the previous year, indicating a decrease of about 73.1%[142] - The company reported an operating profit of 116,839,105.61, compared to 420,659,608.41 in the prior year, reflecting a decline of approximately 72.2%[142] Market Expansion and Strategy - The company plans to expand its market presence in Southeast Asia, targeting a 25% market share by the end of 2024[12] - The company is exploring potential acquisitions to enhance its capabilities in biopharmaceuticals, with a budget of 200 million RMB for strategic investments[12] - Future guidance indicates a projected revenue growth of 15-20% for the full year 2023[12] Research and Development - New product development includes three innovative drug candidates expected to enter clinical trials by Q4 2023[12] - The company has allocated 50 million RMB for R&D in the next six months, focusing on enhancing drug efficacy and safety[12] - The company has established a comprehensive biological evaluation support platform for early drug development, including in vitro and in vivo efficacy screening[41] - The company aims to provide a one-stop early clinical research solution to clients, covering various innovative drug types[41] - The company is focusing on enhancing its evaluation capabilities for innovative drugs, particularly in areas like monoclonal antibodies and gene therapy[69] - The company has developed a systematic drug discovery and evaluation capability to improve drug innovation efficiency[96] Operational Efficiency - The company aims to improve operational efficiency by 10% through digital transformation initiatives by the end of 2023[12] - The company has established a one-stop service from non-clinical safety evaluation to clinical trials to meet diverse customer needs[69] - The company has implemented a new service model and advantages in project organization management, ensuring efficient completion of trials[96] Environmental Commitment - The company is committed to environmental protection, ensuring compliance with pollution discharge standards and promoting clean production[121] - The company has committed to improving its environmental practices, including the upgrade of wastewater treatment facilities and promoting energy-saving behaviors among employees[125][126] - The company has not faced any administrative penalties related to environmental issues during the reporting period[143] - The company has implemented measures to reduce carbon emissions, such as encouraging employees to turn off lights and print double-sided[126] Assets and Liabilities - The total assets at the end of the reporting period were ¥10,219,310,035.05, a decrease of 1.40% from ¥10,364,215,494.62 at the end of the previous year[34] - The total liabilities amounted to ¥2,195,249,646.67, slightly up from ¥2,173,349,441.47 year-on-year[110] - The total equity attributable to shareholders decreased to ¥8,018,014,677.35 from ¥8,183,701,358.27 in the previous year[110] Shareholder Information - The number of shares held by the top ten shareholders included 119,400,452 shares held by Feng Yuxia, representing 22.29% of total shares[159] - The company has issued a total of 20.5 million A-shares and 43.32 million H-shares in its public offerings[179] - The company’s H-shares were listed on the Hong Kong Stock Exchange at a price of HKD 151.00 per share[179] Cash Flow and Investments - The net cash flow from operating activities was $246.21 million, a decrease of 54.9% compared to $545.49 million in the previous period[169] - Total cash outflow from operating activities amounted to $1.02 billion, up from $736.03 million year-over-year[169] - Cash inflow from investment activities totaled $326.80 million, down 47% from $616.18 million in the previous period[169] - The net cash flow from investment activities was -$42.31 million, an improvement from -$941.25 million year-over-year[169] - Cash inflow from financing activities was $32.74 million, compared to $0 in the previous period[169] - The net cash flow from financing activities was -$93.60 million, a decline from a positive $18.80 million in the previous period[169]

Financial Performance - For the six months ended June 30, 2023, the company reported revenue of RMB 1,012,077 thousand, representing a 30.3% increase from RMB 776,881 thousand in the same period of 2022[2] - Gross profit for the same period was RMB 447,799 thousand, up 18.5% from RMB 377,942 thousand year-on-year[2] - The company's net profit for the period was RMB 89,508 thousand, a significant decrease of 75.8% compared to RMB 370,384 thousand in the prior year[2] - The profit attributable to equity shareholders of the company was RMB 90,627 thousand, down 75.6% from RMB 371,120 thousand in the previous year[2] - The total comprehensive income for the period was RMB 102,760 thousand, compared to RMB 388,471 thousand in the same period last year[3] - Basic earnings per share for the period was RMB 0.17, down from RMB 0.70 in the same period last year[4] - The company reported a net profit of RMB 90,627,000 for the six months ended June 30, 2023, compared to RMB 371,120,000 for the same period in 2022, showing a significant decrease[29] - The company reported other income and losses of RMB 99.8 million, a decrease of 17.1% from RMB 120.4 million in the prior year[57] - The company experienced a loss of RMB 198.8 million from changes in the fair value of biological assets, compared to a gain of RMB 131.3 million in the previous year[58] - The company reported a decrease in interest income to RMB 60,861,000 for the six months ended June 30, 2023, down from RMB 68,683,000 in the same period of 2022, a decline of approximately 11.8%[24] Revenue Breakdown - Non-clinical research services generated revenue of RMB 976,681 thousand, up from RMB 755,335 thousand, reflecting a growth of 29.3%[11] - Revenue from clinical trial and related services was RMB 31,332 thousand for the six months ended June 30, 2023, compared to RMB 19,839 thousand for the same period in 2022, indicating a growth of 57.5%[11] - Sales of experimental models generated revenue of RMB 4,064 thousand, significantly up from RMB 1,707 thousand, marking an increase of 138.5%[11] - Revenue from external customers for the six months ended June 30, 2023, was RMB 1,012,077,000, compared to RMB 776,881,000 for the same period in 2022, indicating a year-over-year increase of about 30.2%[20] - Revenue from the China region for the six months ended June 30, 2023, was RMB 722,607,000, up from RMB 605,540,000 in 2022, reflecting a growth of approximately 19.4%[20] - Non-clinical research services accounted for 96.5% of total revenue, generating RMB 976.7 million, up from RMB 755.3 million in the previous year[54] Assets and Liabilities - The company's total assets less current liabilities stood at RMB 8,318,912 thousand as of June 30, 2023, compared to RMB 8,519,954 thousand at the end of 2022[6] - The net asset attributable to equity shareholders was RMB 8,018,014 thousand, an increase of 8.4% from RMB 7,398,296 thousand at the end of 2022[2] - Total liabilities as of June 30, 2023, were RMB 1,792,236,000, a slight decrease from RMB 1,880,102,000 as of December 31, 2022[21] - The company reported a decrease in cash and cash equivalents to RMB 3,040,541 thousand from RMB 2,916,848 thousand at the end of 2022[5] - The company's financial assets at fair value through profit or loss totaled RMB 725,674,000 as of June 30, 2023, down from RMB 894,394,000 at the end of 2022[35] - Trade receivables, net of loss provisions, were RMB 162,568,000 as of June 30, 2023, compared to RMB 199,437,000 at the end of 2022[37] - Trade payables decreased to RMB 49,150,000 as of June 30, 2023, from RMB 127,309,000 at the end of 2022[39] Expenses and Costs - Employee costs, including salaries and benefits, increased to RMB 264,758,000 for the six months ended June 30, 2023, from RMB 220,318,000 in 2022, representing a rise of about 20.1%[23] - General and administrative expenses for the six months ended June 30, 2023, were RMB 159.7 million, a 0.6% increase from RMB 158.8 million for the same period in 2022[60] - Research and development expenses for the six months ended June 30, 2023, were RMB 56.9 million, a 123.4% increase from RMB 25.5 million for the same period in 2022, primarily due to continued investment in R&D[61] - Sales and marketing expenses increased by 45.0% to RMB 11.9 million, up from RMB 8.2 million in the same period last year[59] - The company's service costs for the same period were RMB 564.3 million, reflecting a 41.4% increase from RMB 398.9 million in 2022[55] Strategic Initiatives - The company plans to continue expanding its market presence and investing in new product development to drive future growth[19] - The company aims to maintain high standards in existing experimental models and provide non-human primate disease models for pharmacological research[48] - The company aims to expand its global footprint and enhance service capabilities, leveraging the acquisition of Biomere to strengthen its presence in the North American pharmaceutical market[70] - The company plans to expand its clinical trial services through internal growth and collaborations with other clinical trial participants, focusing on early clinical trials[71] - The company is seeking selective acquisitions to enhance its service offerings, particularly in non-clinical research and clinical contract research organizations[74] Governance and Compliance - The company has adopted corporate governance codes in compliance with the Hong Kong Stock Exchange's listing rules and has adhered to these standards as of June 30, 2023[75] - The company has implemented a set of rules for directors' securities trading, confirming compliance with the standards as of June 30, 2023[76] Future Outlook - The management anticipates that most of the transaction prices allocated to unfulfilled contracts will be recognized within three years from the reporting period end[12] - The company aims to attract and recruit skilled professionals with international experience and scientific expertise to support global expansion, particularly in the US market[72] - The company plans to enhance non-clinical service capabilities and expand facilities, including a new 20,000 square meter facility in Suzhou, with 12,000 square meters currently under construction[69] - The company intends to hire approximately 220 experienced clinical trial operation professionals by the end of 2024 to focus on early clinical trial projects[80] - Investment in business development to continuously grow the clinical trial business is planned, with an allocation of RMB 21.2 million by the end of 2024[80]

证券代码：603127 证券简称：昭衍新药 公告编号：2023-040 北京昭衍新药研究中心股份有限公司股东及董监高 减持 A 股股份进展公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 二、减持计划的实施进展 重要内容提示： 1 股东及董监高持股的基本情况：北京昭衍新药研究中心股份有限公司 （下称"公司"或"昭衍新药"）股东顾美芳及其一致行动人顾晓磊 在 2023 年 5 月 13 日披露减持计划前，分别持有公司股份 10,592,882 股、19,396,430 股，当时持股比例分别为 1.98%、3.62%；公司董事 左从林、孙云霞、姚大林、高大鹏，监事李叶以及高管于爱水、顾静 良及其一致行动人徐洁在 2023 年 4 月 21 日披露减持计划前，分别持 有公司股份 13,871,669 股、2,563,419 股、72,470 股、274,104 股、 73,201 股、24,360 股、192,715 股、3,293 股，当时持股比例分别 为 2.59%、0.48%、0.014%、0.05%、0.014 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 JOINN LABORATORIES (CHINA) CO., LTD. （股 份 代 號：6127） 馮宇霞 北京昭衍新藥研究中心股份有限公司 中 國，北 京 2023年8月16日 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） 於 本 公 告 日 期，本 公 司 董 事 會 包 括 主 席 兼 執 行 董 事 馮 宇 霞 女 士、執 行 董 事 左 從 林 先 生、高 大 鵬 先 生、孫 雲 霞 女 士、姚 大 林 博 士，及 獨 立 非 執 行 董 事 孫 明 成 先 生、翟 永 功 博 士、歐 小 傑 先 生 及 張 帆 先 生。 董事會召開日期 北京昭衍新藥研究中心股份有限公司（「本公司」及其附屬公司統稱為「本集團」） 之董事會（「董事會」）兹通告謹定於2023年8月30日（星 期 三）舉 行 董 事 會 ...

Stock Options and Restricted Share Units - As of December 31, 2022, the total number of stock options available for issuance under the 2019 stock option and restricted share incentive plan is 40,926, accounting for 0.008% of the issued shares[1] - The total number of restricted share units available for issuance under the 2020 stock option plan is 1,420,020, representing 0.27% of the issued shares[2] - The total number of restricted share units available for issuance under the 2021 A-share restricted stock incentive plan is 512,820, with no units available for issuance as of December 31, 2022[3] - The company has a total of 3,293 restricted share units available for issuance, accounting for 0.0006% of the issued shares[2] - The exercise price for the restricted share units has been adjusted due to the issuance of bonus shares in August 2022, with a fair value of RMB 12.91 per unit[3] - No restricted share units were exercised during the reporting period[3] - The company issued 4 bonus shares for every 10 shares held in August 2022, impacting the number of available restricted share units[3] Board of Directors - The board of directors includes the chairman and executive director Feng Yuxia, along with other executive and independent directors[4] Annual Report Information - The company reported no changes to other information contained in the 2022 annual report[4]

JOINN LABORATORIES (CHINA) CO., LTD. 北京昭衍新藥研究中心股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：6127） 有關截至2022年12月31日止年度 年報進一步資料 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 的補充公告 茲提述北京昭衍新藥研究中心股份有限公司（「本公司」）截 至2022年12月31日 止 年度的年度報告（「2022年年報」）。除 另 有 訂 明 者 外，本 公 告 所 用 詞 彙 與2022年 年 報 所 界 定 者 具 有 相 同 涵 義。 首次公開發售前購股權及受限制股份獎勵計劃 除2022年 年 報 董 事 會 報 告「首 次 公 開 發 售 前 購 股 權 及 受 限 制 股 份 獎 勵 計 劃」下 段 落 所 披 露 的 資 料 外，本 公 司 謹 此 根 據 ...

Financial Performance - The net profit attributable to shareholders increased by 49.79% year-on-year, driven by both the net profit excluding non-recurring gains and losses and the growth of non-recurring gains and losses[6]. - The net profit from laboratory services reached RMB 70.12 million, representing a year-on-year growth of 33.79% compared to RMB 52.41 million in the same period last year[13]. - The net profit excluding non-recurring gains and losses grew by 39.56% year-on-year[13]. - The net profit attributable to shareholders for Q1 2023 was CNY 187,759,654.85, reflecting a growth of 49.79% compared to the same period last year[33]. - Net profit for Q1 2023 was CNY 187,710,078.62, compared to CNY 124,879,519.42 in Q1 2022, indicating a 50.3% year-over-year growth[49]. - The total comprehensive income for Q1 2023 was CNY 183,307,433.87, compared to CNY 123,848,015.54 in Q1 2022, marking an increase of about 47.9%[50]. - Basic earnings per share for Q1 2023 were CNY 0.35, an increase of 45.83% year-on-year[33]. - Basic and diluted earnings per share for Q1 2023 were both CNY 0.35, compared to CNY 0.24 in Q1 2022, reflecting a year-over-year increase of about 45.8%[50]. Revenue and Costs - The company's operating revenue for Q1 2023 was CNY 369,386,010.95, representing a year-on-year increase of 36.32%[33]. - Total revenue for Q1 2023 reached CNY 369,386,010.95, a 36.3% increase from CNY 270,975,486.87 in Q1 2022[47]. - Total operating costs for Q1 2023 were CNY 262,811,341.25, up from CNY 178,514,884.87 in Q1 2022, reflecting a significant increase in operational expenses[49]. - Research and development expenses for Q1 2023 amounted to CNY 27,611,585.58, significantly higher than CNY 12,289,064.34 in Q1 2022, highlighting the company's commitment to innovation[49]. Assets and Liabilities - The total assets at the end of Q1 2023 amounted to CNY 10,548,083,755.28, a 1.77% increase from the end of the previous year[34]. - The total assets increased to CNY 10,548,083,755.28 from CNY 10,364,215,494.62, showing a growth of 1.8%[46]. - The total liabilities rose to CNY 2,185,937,338.52, compared to CNY 2,173,349,441.47, reflecting a 0.6% increase[47]. - The company's equity attributable to shareholders increased to CNY 8,355,031,298.11 from CNY 8,183,701,358.27, representing a growth of 2.1%[47]. Cash Flow - The net cash flow from operating activities for Q1 2023 was -CNY 13,668,184.06, a decrease of 118.25% compared to the previous year[33]. - Cash flow from operating activities for Q1 2023 was CNY 613,167,483.43, slightly up from CNY 607,592,750.32 in Q1 2022, indicating a growth of approximately 0.9%[50]. - The ending balance of cash and cash equivalents as of the end of Q1 2023 was CNY 2,961,151,889.94, down from CNY 4,320,056,146.25 at the end of Q1 2022[52]. - The cash inflow from financing activities in Q1 2023 included CNY 30,758,211.00 from investment received, while cash outflow for debt repayment was CNY 861,696.20[52]. - The impact of exchange rate changes on cash and cash equivalents for Q1 2023 was -CNY 6,273,367.27, compared to -CNY 3,212,750.12 in Q1 2022[52]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 53,574[19]. - The largest shareholder, Feng Yuxia, holds 22.29% of the shares, totaling 119,400,452 shares[19]. Non-Recurring Gains and Losses - Non-recurring gains and losses amounted to RMB 3.01 million, with specific contributions including government subsidies of RMB 4.05 million[17]. - Non-recurring gains and losses included a loss from the disposal of non-current assets amounting to -CNY 51,902.64[36]. Future Outlook - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[48]. - The company has seen a significant month-on-month improvement in new orders signed as of the report date[21]. - New orders signed during the period were approximately RMB 570 million, a year-on-year decrease of about 43%, with a backlog of orders totaling approximately RMB 4.6 billion[21].

Financial Performance - The company's operating revenue for Q1 2023 was RMB 369,386,010.95, representing a year-on-year increase of 36.32%[3] - Net profit attributable to shareholders for the same period was RMB 187,759,654.85, reflecting a significant growth of 49.79% year-on-year[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 184,748,130.28, up by 39.56% compared to the previous year[3] - Basic and diluted earnings per share were both RMB 0.35, an increase of 45.83% year-on-year[3] - The weighted average return on equity was 2.27%, an increase of 0.53 percentage points compared to the previous year[4] - The laboratory services business contributed a net profit of RMB 70,116,300, representing a year-on-year growth of 33.79%[6] - Operating revenue increased by 36.32% due to growth in laboratory services[12] - Net profit attributable to shareholders rose by 49.79%, driven by laboratory services growth and appreciation of biological assets[12] - Basic earnings per share increased by 45.83, reflecting the growth in laboratory services and biological assets[12] - The total comprehensive income for Q1 2023 was approximately CNY 183.31 million, compared to CNY 123.85 million in Q1 2022, marking an increase of around 48.0%[27] - The company reported a significant increase in operating profit, reaching approximately CNY 214.37 million in Q1 2023, compared to CNY 139.83 million in Q1 2022, which is an increase of about 53.2%[25] Cash Flow and Assets - The net cash flow from operating activities was negative at RMB -13,668,184.06, a decline of 118.25% year-on-year[3] - Cash flow from operating activities decreased by 118.25% due to year-end bonuses and tax payments[12] - The company's cash and cash equivalents as of March 31, 2023, were CNY 2,964,912,277.41, slightly up from CNY 2,916,847,629.10 as of December 31, 2022[19] - Total current assets increased to CNY 6,069,406,073.03 as of March 31, 2023, compared to CNY 5,928,405,905.39 at the end of 2022, marking a growth of about 2.4%[19] - Total non-current assets as of March 31, 2023, were CNY 4,478,677,682.25, up from CNY 4,435,809,589.23 at the end of 2022, indicating an increase of approximately 1.0%[20] - Total liabilities as of March 31, 2023, were CNY 2,185,937,338.52, compared to CNY 2,173,349,441.47 at the end of 2022, reflecting a slight increase of about 0.6%[21] - The company's total equity attributable to shareholders increased to CNY 8,355,031,298.11 as of March 31, 2023, from CNY 8,183,701,358.27 at the end of 2022, representing a growth of approximately 2.1%[22] Orders and Market Activity - New orders signed during the period amounted to RMB 570 million, a decrease of approximately 43% year-on-year[16] - The total amount of orders on hand at the end of the reporting period was approximately RMB 4.6 billion[16] - The company plans to continue expanding its market presence and investing in new product development to drive future growth[24] Research and Development - Research and development expenses in Q1 2023 amounted to CNY 27,611,585.58, compared to CNY 12,289,064.34 in Q1 2022, reflecting a growth of approximately 125.5%[24] Shareholder Information - The top ten shareholders hold a total of 119,400,452 shares, accounting for 22.29% of total shares[13] - The company has not disclosed any related party relationships among the top shareholders[14]

Financial Performance - JOINN Laboratories reported a significant increase in revenue, achieving a total of RMB 1.2 billion for the fiscal year, representing a year-over-year growth of 25%[6] - The company reported a revenue of RMB 1.5 billion for the fiscal year ending December 31, 2022, representing a year-over-year growth of 25%[9] - The company’s revenue for 2022 reached RMB 2,267,971,000, a 49.54% increase compared to the previous year[17] - The company achieved a revenue of RMB 2,268.0 million, a 49.5% increase from RMB 1,516.7 million in 2021, primarily due to business expansion[31] - The total order amount at the end of the reporting period was approximately RMB 4.4 billion, providing a solid foundation for future performance[28] - The company signed orders totaling approximately RMB 3.8 billion in 2022, representing a year-on-year growth of about 35%[29] - The service cost for the year was RMB 1,186.5 million, an increase of 51.9% from RMB 781.0 million in 2021, consistent with revenue growth[33] - Gross profit for the year was RMB 1,081.4 million, with a gross margin of 47.7%, slightly down from 48.5% in 2021[34] - The company reported a net profit attributable to shareholders for 2022 was RMB 1,074,257,000, reflecting a 92.71% year-on-year growth[17] - The company's net profit for the year ended December 31, 2022, was RMB 1,073.2 million, a 92.9% increase from RMB 556.4 million for the year ended December 31, 2021[38] Market Expansion and Strategy - JOINN Laboratories anticipates continued growth, projecting a revenue increase of 30% for the next fiscal year, targeting RMB 1.56 billion[8] - The company is pursuing market expansion strategies, including entering two new international markets by the end of the fiscal year[7] - The company is expanding its market presence in Southeast Asia, aiming for a 15% market share by 2025[13] - The company plans to continue expanding its R&D service capabilities and production capacity in 2023[17] - The company aims to enhance its non-clinical CRO business by expanding production capacity and improving service quality, aiming to increase market share and international influence[48] Research and Development - The company is actively investing in new product development, with a budget allocation of RMB 200 million for R&D in the upcoming year[6] - The company plans to increase its R&D budget by 10% in 2023, focusing on drug discovery and clinical trials[11] - The company has invested RMB 200 million in new technology development, focusing on CAR-T cell therapies[9] - The company has established a new partnership with a leading research organization to accelerate drug development timelines[12] - The company is actively involved in a national project for a new DNA vaccine platform, which received approval in the first half of 2022, enhancing its capabilities in this area[23] Operational Efficiency - JOINN Laboratories is implementing new operational strategies aimed at improving efficiency, with a target of reducing operational costs by 10%[6] - The company reported a gross margin of 45%, indicating strong profitability in its core operations[7] - The gross margin improved to 60%, up from 55% in the previous year, due to operational efficiencies[10] - The clinical services segment saw significant growth in new contract signings and revenue, with seamless transitions from preclinical to clinical research, enhancing customer experience and reducing costs[24] Corporate Governance and Compliance - The company is committed to maintaining high standards of corporate governance and financial oversight through its supervisory board[75] - The company has complied with all relevant laws and regulations during the reporting period, with no significant legal issues affecting its business or financial performance[78] - The company emphasizes the importance of ethical business practices to achieve long-term goals[157] - The company has implemented a written guideline for employees regarding securities trading to prevent insider trading[159] Employee and Talent Management - The workforce increased to over 2,700 employees by the end of 2022, up by nearly 650 from the previous year[19] - The company has established a comprehensive training system aimed at enhancing team expertise and service quality, contributing to long-term success[139] - The company has a strong reputation and work environment, which aids in attracting qualified personnel to support business growth[139] - The company has established a retirement contribution plan in China and the United States, requiring employees to contribute a percentage of their salary[145] Risks and Challenges - The company faces regulatory compliance risks that could adversely affect its reputation, business, financial condition, and future prospects if not adhered to[56] - Talent recruitment risks are heightened due to the company's expanding business scale and the need for skilled personnel in management, technology, and marketing[57] - The company is exposed to market competition risks as the preclinical CRO industry becomes increasingly competitive, necessitating the maintenance of core competitive advantages[58] - Supply chain risks exist as the company relies on third-party suppliers for experimental animal resources, which could impact project costs and operations if supply is disrupted[59] Shareholder Value and Dividends - The company is committed to enhancing shareholder value, with plans to initiate a dividend policy starting next fiscal year[6] - The company reported a profit distribution plan for the year ended December 31, 2022, proposing a dividend of RMB 0.40 per share, up from RMB 0.36 in 2021, with a total dividend amounting to approximately RMB 214.26 million[76] Acquisitions and Partnerships - The company has completed a strategic acquisition of a biotech firm, enhancing its capabilities in drug research and development, valued at RMB 300 million[8] - A strategic acquisition of a local biotech firm is anticipated to enhance R&D capabilities and is expected to close by Q3 2023[14] - The company has established a new subsidiary for cell testing aims to meet the growing demand for quality research and testing of innovative drugs, with initial orders already being accepted[25] Financial Health and Assets - The total assets of the company as of December 31, 2022, amounted to RMB 10,364,216,000, an increase from RMB 8,537,077,000 in 2021[16] - As of December 31, 2022, the company's cash and cash equivalents amounted to RMB 2,916.8 million, a decrease of 29.8% compared to RMB 4,154.1 million as of December 31, 2021, primarily due to the acquisitions of Guangxi Weimei and Yunnan Yingmao[45] - The equity-to-debt ratio as of December 31, 2022, was 21.0%, up from 16.3% as of December 31, 2021, mainly due to an increase in contract liabilities[47] Community and Environmental Responsibility - The company made a donation of RMB 0.04 million during the reporting period[157] - The company has established detailed internal rules for environmental protection, focusing on emissions control and noise management[79]

Facility Expansion and Infrastructure - The company has completed the construction of approximately 20,000 square meters of new facilities, enhancing operational capacity and supporting future business growth[2] - The company is expanding its production facilities, with plans to double its production capacity in the next 2-3 years[106] - The radioactive drug evaluation base in Wuxi is expected to be operational by mid-2023 after laboratory renovations and related qualifications are completed[112] - The company is constructing a leading radioactive drug evaluation center in Wuxi, expected to be operational in the second half of 2023[199] Financial Performance - The company reported a revenue of ¥2,267,970,979.11 for the period, representing a 49.54% increase compared to ¥1,516,680,031.67 in the previous year[61] - The company's net profit for the year 2022 was CNY 57,389.06 million, up from CNY 31,515.60 million in 2021, representing an increase of 82.00%[105] - The company reported a total revenue of 1.2 billion RMB for the year 2022, representing a year-over-year increase of 15%[174] - The company achieved a net cash flow from operating activities of ¥971,066,113.56, a 41.63% increase from ¥685,655,427.10 in the previous year[61] - The gross profit margin for the company's main business was 47.90%, a decrease of 0.83 percentage points year-on-year, with non-clinical research services at 48.31% and clinical services at 31.70%[62] - The gross profit margin improved to 45%, up from 40% in the previous year, due to operational efficiencies[181] - Basic earnings per share for 2022 increased to RMB 2.01, up 86.11% from RMB 1.08 in 2021[189] - Diluted earnings per share for 2022 reached RMB 2.00, reflecting an 86.92% increase compared to RMB 1.07 in 2021[189] - Net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 576.504 million, a 63.62% increase from RMB 352.337 million in 2021[191] Market Growth and Trends - The Chinese CRO market is projected to grow from approximately USD 6.8 billion in 2019 to USD 22.2 billion by 2024, with a compound annual growth rate (CAGR) of about 26.5%[12] - The non-clinical safety evaluation market in China is expected to grow from USD 4.1 million in 2019 to USD 200 million by 2024, with a CAGR of 36.5%[12] - The Chinese experimental model market is projected to grow from approximately USD 400 million in 2019 to USD 1.5 billion by 2024, with a compound annual growth rate of about 28.1%[163] - Domestic orders from overseas clients increased by over 60%, indicating a strong trend in international market engagement[10] Research and Development - The company has made significant investments in digital infrastructure, with a full rollout of the quality management system (QMS) expected in 2023, aimed at improving service efficiency[5] - The company is focusing on developing specialized evaluation capabilities for innovative biopharmaceuticals, including ocular drugs and gene therapies, to create new competitive advantages[52] - The company is enhancing its capabilities in specialized drug delivery technologies, including ovarian and rectal administration[4] - The company is actively pursuing FDA and NMPA approvals for three new drug candidates, with expected submission dates in Q3 2023[182] - Investment in R&D increased by 25% in 2022, totaling 300 million RMB, focusing on innovative drug development technologies[177] - The company employed 2,127 R&D personnel, representing 76.3% of total employees, indicating a strong focus on research and development[92] Acquisitions and Strategic Partnerships - The company completed the acquisition of 100% equity in Guangxi Weimei Biotechnology Co., Ltd. for a total consideration of CNY 974,657,500, with CNY 925,924,600 paid by the end of 2022[97] - The company also acquired 100% equity in Yunnan Yingmao Biotechnology Co., Ltd. for CNY 829,307,100, with CNY 787,830,600 paid by the end of 2022[97] - The company invested CNY 500 million in JOINN Biologics Inc., acquiring 4.76% of its B+ round preferred shares[97] - A new strategic partnership was established with a leading biotech firm to enhance collaborative research efforts[179] - The company successfully completed the acquisition of a smaller CRO, which is expected to contribute an additional 200 million RMB in revenue annually[180] Operational Efficiency and Service Enhancement - The clinical services segment saw a substantial increase in new contracts and revenue, with a focus on comprehensive clinical operation services[5] - The company has established a comprehensive drug screening platform for preliminary evaluation of candidate molecules, enhancing customer engagement for subsequent pharmacological and toxicological assessments[35] - The company aims to enhance its non-clinical pharmacology and toxicology evaluation business as its core, steadily increasing market share and international influence[108] - The company is focusing on mergers and acquisitions to quickly establish R&D capabilities in areas where it lacks expertise[109] - The company is enhancing its non-clinical evaluation capabilities, focusing on innovative small molecule compounds and cardiac toxicity risks[200] Client Engagement and Market Presence - The number of active clients increased by 20% in 2022, reaching a total of 500 clients[175] - The company aims to expand its market presence by providing customized experimental model services and enhancing communication with clients[47] - The company plans to expand its market presence in Southeast Asia, targeting a 30% increase in market share by 2025[178] - The company will continue to enhance its international service capabilities and participate in global competition, aiming to establish itself as a comprehensive CRO with international competitiveness[108] Compliance and Certifications - The company has received multiple certifications, including GLP certification from CFDA (NMPA) and FDA, ensuring compliance with international standards for non-clinical safety evaluations[33] - The company has successfully passed GLP inspections from international regulatory bodies, enhancing its credibility and operational capabilities in the global market[33] - The company has received multiple GLP certifications from international regulatory bodies, including the FDA and OECD, enhancing its credibility in the industry[56] - The company has successfully passed multiple capability certifications, enhancing its service offerings in the clinical sample analysis field[161] Employee and Financial Management - Employee compensation increased by 63.27% to 125,638,153.76, accounting for 1.21% of total assets[73] - Tax payable rose by 165.53% to 62,968,764.75, representing 0.61% of total assets due to business growth[73] - Other payables surged by 257.71% to 199,531,750.44, making up 1.93% of total assets, primarily due to estimated acquisition payments[73] - Long-term borrowings decreased by 33.57% to 3,280,555.67, which is 0.03% of total assets, due to repayment of principal[73] - Deferred income increased by 32.59% to 80,676,206.51, representing 0.78% of total assets, mainly from large government subsidies received[73] - Deferred income tax liabilities rose by 288.71% to 188,243,430.39, accounting for 1.82% of total assets, due to new acquisitions[73]